Datamonitor Healthcare: 医療用医薬品の市場調査レポート

NASH Disease Coverage Extract

16 Aug 2019

Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.   

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Six of the Greatest Therapeutic R and D Challenges

16 Aug 2019

Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo.  This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.  

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Oncology Market Leaders Maintain Their Upper Hand

14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts. 

Trialtrove: 医療用医薬品の臨床試験情報データベース

Trialtrove 2018 Completed Clinical Trials Snapshot

12 Aug 2019

Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.  

Trialtrove: 医療用医薬品の臨床試験情報データベース

2018 Completed Trials: State of Industry-Sponsored Clinical Development

06 Aug 2019

The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.

Clinical Trials State of the Industry Report 2019

30 Jul 2019

KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.

Biomedtracker: 開発中医薬品をFDA承認確率で評価

Biomedtracker Q3 2019 Outlook Report Extract

29 Jul 2019

In this report, we cover catalysts from 27 drugs, devices and diagnostics expected to occur in Q3 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.   

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Medicare Price Inflation Rebates, Part D ‘Redesign’ Proposed In Senate Finance Bill

26 Jul 2019

Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.